Duluth Holdings (DLTH) Surpasses Wall Street’s Estimates; Upside Foreseen for Aurinia Pharmaceuticals (AUPH)
Shares of Duluth Holdings Inc. (Nasdaq:DLTH) climbed more than 18% in after-hours trading Tuesday as the company delivered in its financial results quarterly profit and revenue numbers that exceeded Wall Street analysts’ expectations.
For the fourth quarter 2016, Duluth posted net sales of $174.7 million and net income of $14.0 million or $0.43 per diluted share, easily surpassing the Capital IQ Consensus Estimate of $0.34 earnings per share on revenues of $163.74 million for the period.
According to its business outlook, Duluth expects 2017 net sales to be between $455.0 million and $465.0 million, topping the Capital IQ Consensus Estimate of $448.35 million in revenues for the period.
DLTH stock finished the regular session at $19.26, down $0.04 (or -0.21%) with a total volume of 349,297 shares traded.
Duluth Holdings, which sells casual wear, workwear, and accessories for men and women, has 29.01M shares outstanding and DLTH stock 52-week range is between $17.02 and $38.19 per share. At close on Tuesday, the company had a market capitalization of $623.56M
Analysts at FBR & Co. reiterated an Outperform rating and raised their price target on Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH) shares from $9.00 to $11.00, suggesting a potential upside of 31.42% from the stock’s closing price on Tuesday of $8.37
Aurinia Pharmaceuticals, which engages in the development of a therapeutic drug to treat autoimmune diseases, has 53.43M shares outstanding, market capitalization (intraday) of $457.64M and AUPH stock one-year range is from $1.74 to $10.54 per share.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/